{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:24:58Z","timestamp":1784291098135,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014470","name":"Mundipharma International Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014470","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmorw.2025.100677","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:45:18Z","timestamp":1771508718000},"page":"100677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Registry-based randomised phase II study of Enzalutamide versus Abiraterone: assessing cognitive function in eLderly patients with metastatic castration-resistant Prostate cancer (REAL-Pro)"],"prefix":"10.1016","volume":"11","author":[{"given":"A.","family":"Anton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Steer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Arasaratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Weickhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.A.","family":"Mislang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Linton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.esmorw.2025.100677_bib1","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmorw.2025.100677_bib2","series-title":"Cancer Data in Australia","year":"2024"},{"issue":"suppl 15","key":"10.1016\/j.esmorw.2025.100677_bib3","article-title":"FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: a 10-year experience by the U.S. Food and Drug Administration","volume":"35","author":"Singh","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmorw.2025.100677_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2023.101621","article-title":"Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: analysis of an Australian real-world cohort","volume":"14","author":"Fernando","year":"2023","journal-title":"J Geriatr Oncol"},{"issue":"12","key":"10.1016\/j.esmorw.2025.100677_bib5","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmorw.2025.100677_bib6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.euros.2022.04.016","article-title":"Enzalutamide versus abiraterone plus prednisolone before chemotherapy for castration-resistant prostate cancer: a multicenter randomized controlled trial","volume":"41","author":"Izumi","year":"2022","journal-title":"Eur Urol Open Sci"},{"issue":"4","key":"10.1016\/j.esmorw.2025.100677_bib7","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/s41391-024-00816-0","article-title":"Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer","volume":"27","author":"George","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"suppl 2","key":"10.1016\/j.esmorw.2025.100677_bib8","article-title":"1886P Expectations and priorities of older patients with cancer: the PRIORITY multicenter cohort study","volume":"35","author":"Grellety","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmorw.2025.100677_bib9","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3390\/cancers14051147","article-title":"Patient preferences for treatment outcomes in oncology with a focus on the older patient\u2014a systematic review","volume":"14","author":"Seghers","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.esmorw.2025.100677_bib10","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.eururo.2019.09.019","article-title":"Impact of abiraterone acetate plus prednisone or enzalutamide on patient-reported outcomes in patients with metastatic castration-resistant prostate cancer: final 12-mo analysis from the observational AQUARiUS study","volume":"77","author":"Thiery-Vuillemin","year":"2020","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100677_bib11","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.eururo.2018.12.015","article-title":"Health-related quality of life for abiraterone plus prednisone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: results from a phase II randomized trial","volume":"75","author":"Khalaf","year":"2019","journal-title":"Eur Urol"},{"issue":"33","key":"10.1016\/j.esmorw.2025.100677_bib12","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1200\/JCO.2016.67.5926","article-title":"Comprehensive geriatric assessment-guided therapy does improve outcomes of older patients with advanced lung cancer","volume":"34","author":"Gajra","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmorw.2025.100677_bib13","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1016\/S2666-7568(22)00169-6","article-title":"Integrated geriatric assessment and treatment effectiveness (INTEGERATE) in older people with cancer starting systemic anticancer treatment in Australia: a multicentre, open-label, randomised controlled trial","volume":"3","author":"Soo","year":"2022","journal-title":"Lancet Healthy Longev"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100677_bib14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/ajco.12992","article-title":"Re-inventing the randomized controlled trial in medical oncology: the registry-based trial","volume":"14","author":"Foroughi","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.esmorw.2025.100677_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1494073","article-title":"The value of real world evidence and pragmatic trials in advanced prostate cancer-insights from the electronic Prostate Cancer Australian and Asian Database","volume":"14","author":"Anton","year":"2024","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100677_bib16","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1176\/ajp.140.6.734","article-title":"Validation of a short Orientation-Memory-Concentration Test of cognitive impairment","volume":"140","author":"Katzman","year":"1983","journal-title":"Am J Psychiatry"},{"issue":"9","key":"10.1016\/j.esmorw.2025.100677_bib17","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1200\/OP.23.00263","article-title":"Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline questions and answers","volume":"19","author":"Williams","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"8","key":"10.1016\/j.esmorw.2025.100677_bib18","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.jgo.2020.07.008","article-title":"Adapting care for older cancer patients during the COVID-19 pandemic: recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 working group","volume":"11","author":"Battisti","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"9","key":"10.1016\/j.esmorw.2025.100677_bib19","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/cncr.21422","article-title":"Developing a cancer-specific geriatric assessment: a feasibility study","volume":"104","author":"Hurria","year":"2005","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100677_bib20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jsr.2011.08.006","article-title":"Validating an evidence-based, self-rated fall risk questionnaire (FRQ) for older adults","volume":"42","author":"Rubenstein","year":"2011","journal-title":"J Safety Res"},{"issue":"9","key":"10.1016\/j.esmorw.2025.100677_bib21","first-page":"3681","article-title":"Fall-risk prediction in older adults with cancer: an unmet need","volume":"24","author":"Wildes","year":"2016","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.esmorw.2025.100677_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0022-3956(82)90033-4","article-title":"Development and validation of a geriatric depression screening scale: a preliminary report","volume":"17","author":"Yesavage","year":"1982","journal-title":"J Psychiatr Res"},{"issue":"393","key":"10.1016\/j.esmorw.2025.100677_bib23","first-page":"195","article-title":"Evaluation of the feasibility, reliability and diagnostic value of shortened versions of the geriatric depression scale","volume":"45","author":"van Marwijk","year":"1995","journal-title":"Br J Gen Pract"},{"issue":"suppl 15","key":"10.1016\/j.esmorw.2025.100677_bib24","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1200\/JCO.2016.34.15_suppl.5059","article-title":"Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"34","author":"Parimi","year":"2016","journal-title":"J Clin Oncol"},{"issue":"suppl 9","key":"10.1016\/j.esmorw.2025.100677_bib25","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/OP.24.00036","article-title":"Impact of comorbidities and drug interactions in patients with metastatic castration-resistant prostate cancer receiving androgen receptor pathway inhibitors","volume":"20","author":"Zhong","year":"2024","journal-title":"JCO Oncol Pract"},{"issue":"suppl 5","key":"10.1016\/j.esmorw.2025.100677_bib26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1200\/JCO.2025.43.5_suppl.131","article-title":"Cognitive effects of androgen receptor (AR) directed therapies for advanced cancer of the prostate (COGCaP): a comparison of enzalutamide vs abiraterone acetate","volume":"43","author":"Morgans","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmorw.2025.100677_bib27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2024.42.4_suppl.20","article-title":"Multi-centre prospective evaluation of cognitive function in patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) or enzalutamide (ENZ): the ACE study","volume":"42","author":"Bahl","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100677_bib28","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/OP.20.00442","article-title":"How is geriatric assessment used in clinical practice for older adults with cancer? A survey of cancer providers by the American Society of Clinical Oncology","volume":"17","author":"Dale","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"7","key":"10.1016\/j.esmorw.2025.100677_bib29","doi-asserted-by":"crossref","first-page":"e1081","DOI":"10.1200\/OP.21.00743","article-title":"The use and knowledge of validated geriatric assessment instruments among US community oncologists","volume":"18","author":"Gajra","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"10.1016\/j.esmorw.2025.100677_bib30","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jgo.2018.07.004","article-title":"Utilisation of geriatric assessment in oncology \u2013 a survey of Australian medical oncologists","volume":"10","author":"To","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.esmorw.2025.100677_bib31","doi-asserted-by":"crossref","first-page":"114313","DOI":"10.1016\/j.ejca.2024.114313","article-title":"Improving completion rates of patient-reported outcome measures in cancer clinical trials: scoping review investigating the implications for trial designs","volume":"212","author":"van der Weijst","year":"2024","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmorw.2025.100677_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2024.102148","article-title":"Real-world effectiveness and cardiovascular safety of abiraterone versus enzalutamide amongst older patients diagnosed with metastatic castration-resistant prostate cancer","volume":"16","author":"Gaber","year":"2025","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.esmorw.2025.100677_bib33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejca.2021.05.003","article-title":"Effectiveness of first-line abiraterone versus enzalutamide among patients \u226580 years of age with metastatic castration-resistant prostate cancer: a retrospective propensity score-weighted comparative cohort study","volume":"152","author":"Soleimani","year":"2021","journal-title":"Eur J Cancer"},{"issue":"suppl 5","key":"10.1016\/j.esmorw.2025.100677_bib34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2025.43.5_suppl.20","article-title":"Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD)","volume":"43","author":"Fisher","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmorw.2025.100677_bib35","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.esmorw.2025.100677_bib36","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmorw.2025.100677_bib37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/bco2.129","article-title":"Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer","volume":"3","author":"Anton","year":"2022","journal-title":"BJUI Compass"},{"issue":"7","key":"10.1016\/j.esmorw.2025.100677_bib38","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/oncolo\/oyae019","article-title":"Extended safety and tolerability of darolutamide for nonmetastatic castration-resistant prostate cancer and adverse event time course in ARAMIS","volume":"29","author":"Shore","year":"2024","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.esmorw.2025.100677_bib39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13063-023-07109-2","article-title":"\u201cNothing to lose and the possibility of gaining\u201d: a qualitative study on the feasibility and acceptability of registry-based randomised controlled trials among cancer patients and clinicians","volume":"24","author":"Prang","year":"2023","journal-title":"Trials"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820125005661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820125005661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:24:23Z","timestamp":1774488263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820125005661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":39,"alternative-id":["S2949820125005661"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2025.100677","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Registry-based randomised phase II study of Enzalutamide versus Abiraterone: assessing cognitive function in eLderly patients with metastatic castration-resistant Prostate cancer (REAL-Pro)","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2025.100677","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100677"}}